SCHEMBL14545786

SCHEMBL14545786

CC(C)N1CCC(c2ccc(F)c(F)c2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 2/20 0.46
DRD2 P14416 1/20 0.46
ESRRG P62508 2/20 0.39
ESRRB O95718 1/20 0.39
ESR1 P03372 1/20 0.39
MCOLN2 Q8IZK6 1/20 0.38
BMPR1B O00238 1/20 0.38
BMPR1A P36894 1/20 0.38
TGFBR1 P36897 1/20 0.38
ACVRL1 P37023 1/20 0.38
ACVR1 Q04771 1/20 0.38
PARP1 P09874 1/20 0.38
USP30 Q70CQ3 1/20 0.38
CCR1 P32246 1/20 0.37
GRIA4 P48058 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
CHRM2 P08172 1/20 0.36
HTR1A P08908 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13698248 0.88 DRD2 (0.44) DRD3DRD2ESRRGESRRBESR1
SCHEMBL14136276 0.88 DRD2 (0.44) DRD3DRD2ESRRGESRRBESR1
SCHEMBL24877484 0.87 SLC6A2 (0.40) DRD3DRD2ESRRGUSP30GRIA4
SCHEMBL13698216 0.87 DRD2 (0.43) DRD3DRD2MCOLN2SLC6A2SLC6A4
SCHEMBL2603286 0.82 KCNH2 (0.47) DRD3DRD2ESRRGESRRBESR1
SCHEMBL23993613 0.82 KCNH2 (0.47) DRD3DRD2ESRRGESRRBESR1
SCHEMBL10057694 0.80 DRD3 (0.54) DRD3DRD2ESRRGMCOLN2CHRM2
SCHEMBL1820343 0.79 SLC6A2 (0.49) DRD3DRD2USP30SLC6A2SLC6A4
SCHEMBL26869113 0.79 DRD2 (0.50) DRD3DRD2ESRRGESRRBESR1
SCHEMBL13698254 0.78 SLC6A4 (0.56) DRD3DRD2SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070082940-A1 Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders OTSUKA AMERICA PHARMACEUTICAL, INC. 2007-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070082940-A1 Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders HTR3C, HTR1B, HTR2C DRD3 32/4885DRD2 35/4885ESRRG 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.